Biotech Values

[dewophile]

The patients in the EDP-514 trial reported on today were nuke-suppressed, which means they had very low viral loads at baseline. That’s why the mean reduction in HBV RNA from baseline was only 1.0 logs (at 28 days) in the EDP-514 arms.

I am assuming these patients have HBV DNA that is undetectable at baseline, so vial loads per se have no further room to go down. These patients still have circulating RNA, which can then serve (supposedly) as a surrogate for cccDNA. At least that is my understanding - maybe they clarified on the cc but I haven't gotten to it yet